These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

411 related articles for article (PubMed ID: 25743376)

  • 41. Safety and efficacy of 12-week or longer indacaterol treatment in moderate-to-severe COPD patients: a systematic review.
    Jiang FM; Liang ZA; Zheng QL; Wang RC; Luo J; Li CT
    Lung; 2013 Apr; 191(2):135-46. PubMed ID: 23306410
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of airway dimensions with once daily tiotropium plus indacaterol versus twice daily Advair(®) in chronic obstructive pulmonary disease.
    Hoshino M; Ohtawa J; Akitsu K
    Pulm Pharmacol Ther; 2015 Feb; 30():128-33. PubMed ID: 25183687
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of clinical efficacy and safety between indacaterol and tiotropium in COPD: meta-analysis of randomized controlled trials.
    Kim JS; Park J; Lim SY; Oh YM; Yoo KH; Park YB; Sheen SS; Kim MJ; Carriere KC; Jung JY; Park HY
    PLoS One; 2015; 10(3):e0119948. PubMed ID: 25799171
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease.
    McKeage K
    Drugs; 2012 Mar; 72(4):543-63. PubMed ID: 22356291
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of indacaterol on dynamic lung hyperinflation and breathlessness in hyperinflated patients with COPD.
    Beeh KM; Wagner F; Khindri S; Drollmann AF
    COPD; 2011 Oct; 8(5):340-5. PubMed ID: 21793716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Indacaterol--a new hope for maximising bronchodilation?].
    Mihălţan F
    Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparative efficacy of combination bronchodilator therapies in COPD: a network meta-analysis.
    Huisman EL; Cockle SM; Ismaila AS; Karabis A; Punekar YS
    Int J Chron Obstruct Pulmon Dis; 2015; 10():1863-81. PubMed ID: 26392761
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study.
    Beeh KM; Korn S; Beier J; Jadayel D; Henley M; D'Andrea P; Banerji D
    Respir Med; 2014 Apr; 108(4):584-92. PubMed ID: 24534204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Influence of indacaterol on daily physical activity in patients with untreated chronic obstructive pulmonary disease.
    Nishijima Y; Minami S; Yamamoto S; Ogata Y; Koba T; Futami S; Komuta K
    Int J Chron Obstruct Pulmon Dis; 2015; 10():439-44. PubMed ID: 25767381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study.
    Dahl R; Chapman KR; Rudolf M; Mehta R; Kho P; Alagappan VK; Chen H; Banerji D
    Respir Med; 2013 Oct; 107(10):1558-67. PubMed ID: 23867808
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Once-daily long-acting beta-agonists for chronic obstructive pulmonary disease: an indirect comparison of olodaterol and indacaterol.
    Roskell NS; Anzueto A; Hamilton A; Disse B; Becker K
    Int J Chron Obstruct Pulmon Dis; 2014; 9():813-24. PubMed ID: 25114521
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
    Renard D; Looby M; Kramer B; Lawrence D; Morris D; Stanski DR
    Respir Res; 2011 Apr; 12(1):54. PubMed ID: 21518459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and Safety of Indacaterol/Glycopyrronium (IND/GLY) Versus Salmeterol/Fluticasone in Chinese Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: The Chinese Cohort from the LANTERN Study.
    Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Patalano F; Banerji D
    COPD; 2016 Dec; 13(6):686-692. PubMed ID: 27715335
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.
    Vogelmeier C; Ramos-Barbon D; Jack D; Piggott S; Owen R; Higgins M; Kramer B;
    Respir Res; 2010 Oct; 11(1):135. PubMed ID: 20920365
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data.
    Bleecker ER; Siler T; Owen R; Kramer B
    Int J Chron Obstruct Pulmon Dis; 2011; 6():431-8. PubMed ID: 22003288
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparative efficacy of indacaterol 150 μg and 300 μg versus fixed-dose combinations of formoterol + budesonide or salmeterol + fluticasone for the treatment of chronic obstructive pulmonary disease--a network meta-analysis.
    Cope S; Capkun-Niggli G; Gale R; Jardim JR; Jansen JP
    Int J Chron Obstruct Pulmon Dis; 2011; 6():329-44. PubMed ID: 21697997
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
    Singh MP
    Int J Chron Obstruct Pulmon Dis; 2013; 8():613-9. PubMed ID: 24353411
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis.
    Donohue JF; Betts KA; Du EX; Altman P; Goyal P; Keininger DL; Gruenberger JB; Signorovitch JE
    Int J Chron Obstruct Pulmon Dis; 2017; 12():367-381. PubMed ID: 28176892
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.
    Chapman KR; Rennard SI; Dogra A; Owen R; Lassen C; Kramer B;
    Chest; 2011 Jul; 140(1):68-75. PubMed ID: 21349928
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.